TW202308694A - Pd-1抗體之醫藥組合物及其用途 - Google Patents

Pd-1抗體之醫藥組合物及其用途 Download PDF

Info

Publication number
TW202308694A
TW202308694A TW111125067A TW111125067A TW202308694A TW 202308694 A TW202308694 A TW 202308694A TW 111125067 A TW111125067 A TW 111125067A TW 111125067 A TW111125067 A TW 111125067A TW 202308694 A TW202308694 A TW 202308694A
Authority
TW
Taiwan
Prior art keywords
cancer
pharmaceutical composition
revelizumab
composition
container
Prior art date
Application number
TW111125067A
Other languages
English (en)
Chinese (zh)
Inventor
克里希南 桑帕庫馬爾
彥 周
史蒂芬 詹姆斯 伯克
Original Assignee
美商宏觀基因股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商宏觀基因股份有限公司 filed Critical 美商宏觀基因股份有限公司
Publication of TW202308694A publication Critical patent/TW202308694A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW111125067A 2021-07-09 2022-07-05 Pd-1抗體之醫藥組合物及其用途 TW202308694A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09
US63/220,006 2021-07-09

Publications (1)

Publication Number Publication Date
TW202308694A true TW202308694A (zh) 2023-03-01

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111125067A TW202308694A (zh) 2021-07-09 2022-07-05 Pd-1抗體之醫藥組合物及其用途

Country Status (17)

Country Link
US (2) US12364756B2 (https=)
EP (1) EP4366692A1 (https=)
JP (1) JP2024525566A (https=)
KR (1) KR20240035533A (https=)
CN (1) CN118215465A (https=)
AR (1) AR126404A1 (https=)
AU (1) AU2022307332A1 (https=)
CA (1) CA3224640A1 (https=)
CL (1) CL2024000077A1 (https=)
CO (1) CO2024000198A2 (https=)
CR (1) CR20240065A (https=)
EC (1) ECSP24008791A (https=)
IL (1) IL309985A (https=)
MX (1) MX2024000268A (https=)
PE (1) PE20240797A1 (https=)
TW (1) TW202308694A (https=)
WO (1) WO2023283049A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1946776T (pt) * 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
WO2017019846A1 (en) * 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US12150990B2 (en) * 2017-11-02 2024-11-26 Nanjing Shunxin Pharmaceutical Co., Ltd. Pharmaceutical composition of humanized monoclonal anti-PD-L1 antibody
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
EP4007602A1 (en) * 2019-08-01 2022-06-08 Incyte Corporation A dosing regimen for an ido inhibitor
PH12022550244A1 (en) * 2019-08-05 2022-12-12 Nat Cancer Ct Biomarkers for determining the efficacy of immune checkpoint inhibitors

Also Published As

Publication number Publication date
WO2023283049A1 (en) 2023-01-12
CA3224640A1 (en) 2023-01-12
MX2024000268A (es) 2024-01-31
KR20240035533A (ko) 2024-03-15
CN118215465A (zh) 2024-06-18
AU2022307332A1 (en) 2024-01-18
ECSP24008791A (es) 2024-03-01
JP2024525566A (ja) 2024-07-12
US20230025464A1 (en) 2023-01-26
CL2024000077A1 (es) 2024-08-23
EP4366692A1 (en) 2024-05-15
CO2024000198A2 (es) 2024-02-05
IL309985A (en) 2024-03-01
US12364756B2 (en) 2025-07-22
AR126404A1 (es) 2023-10-11
CR20240065A (es) 2024-04-08
PE20240797A1 (es) 2024-04-18
US20250345422A1 (en) 2025-11-13

Similar Documents

Publication Publication Date Title
US12485173B2 (en) Pharmaceutical products and stable liquid compositions of IL-17 antibodies
JP6396565B2 (ja) 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤
TWI733664B (zh) 包含抗ｐｄ１抗體及另一種抗體之組合的組合物
JP2020516608A (ja) 安定な抗体製剤
JP7674369B2 (ja) 安定な抗体製剤
JP2019536761A (ja) 液体医薬組成物
KR20210114989A (ko) 치료 항체 제제
TW202308694A (zh) Pd-1抗體之醫藥組合物及其用途
HK40112469A (zh) Pd-1抗体的药物组合物及其用途
EA050933B1 (ru) Фармацевтические композиции антитела к pd-1 и применение указанной композиции
TW202310874A (zh) Ｂ７－ｈ３抗體的藥物組合物及其用途
WO2025140467A1 (zh) 稳定的高浓度抗pd-1抗体药物制剂
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
HK40102521A (zh) Her2/neu抗体的药物组合物及其用途
TW202237185A (zh) Ｈｅｒ２／ｎｅｕ抗體的藥物組合物及其用途
HK40115478A (zh) 抗cd22抗体的水性制剂及其用途
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same